Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...
The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an update to the prescribing information ...
PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...
The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes. Insulin degludec, the ultra long-acting basal insulin from Novo ...
PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...
Two products for the treatment of type 2 diabetes, insulin degludec (Tresiba) and liraglutide (Victoza), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for ...
Novo Nordisk's long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes. Novo Nordisk’s long-acting insulin Tresiba has been approved for use by ...
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin Tresiba in Europe at a 60-70 percent premium over rival product Lantus from ...
(RTTNews) - Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback